Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(4.44)
# 296
Out of 5,241 analysts
25
Total ratings
53.57%
Success rate
32.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CING Cingulate | Maintains: Buy | $16 → $14 | $4.48 | +212.50% | 5 | Mar 23, 2026 | |
| CRVO CervoMed | Maintains: Buy | $19 → $11 | $3.04 | +261.84% | 5 | Mar 18, 2026 | |
| NRSN NeuroSense Therapeutics | Initiates: Buy | $3 | $0.7703 | +289.46% | 1 | Mar 10, 2026 | |
| OVID Ovid Therapeutics | Initiates: Buy | $3 | $2.41 | +24.48% | 1 | Dec 11, 2025 | |
| PYPD PolyPid | Maintains: Buy | $10 → $9 | $4.73 | +90.27% | 3 | Nov 13, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $12 → $13 | $28.02 | -53.60% | 3 | Nov 12, 2025 | |
| RNA Atrium Therapeutics | Initiates: Buy | $62 | $12.95 | +378.76% | 1 | Sep 17, 2025 | |
| LGVN Longeveron | Maintains: Buy | $10 → $3 | $0.6761 | +343.72% | 2 | Aug 15, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 → $6 | $1.62 | +270.37% | 3 | Aug 13, 2025 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $5.89 | +392.36% | 1 | Dec 5, 2024 |
Cingulate
Mar 23, 2026
Maintains: Buy
Price Target: $16 → $14
Current: $4.48
Upside: +212.50%
CervoMed
Mar 18, 2026
Maintains: Buy
Price Target: $19 → $11
Current: $3.04
Upside: +261.84%
NeuroSense Therapeutics
Mar 10, 2026
Initiates: Buy
Price Target: $3
Current: $0.7703
Upside: +289.46%
Ovid Therapeutics
Dec 11, 2025
Initiates: Buy
Price Target: $3
Current: $2.41
Upside: +24.48%
PolyPid
Nov 13, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $4.73
Upside: +90.27%
Capricor Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $28.02
Upside: -53.60%
Atrium Therapeutics
Sep 17, 2025
Initiates: Buy
Price Target: $62
Current: $12.95
Upside: +378.76%
Longeveron
Aug 15, 2025
Maintains: Buy
Price Target: $10 → $3
Current: $0.6761
Upside: +343.72%
Gain Therapeutics
Aug 13, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $1.62
Upside: +270.37%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $5.89
Upside: +392.36%